Brokerages Set Opthea Limited Unsponsored ADR (NASDAQ:OPT) PT at $1.33

Shares of Opthea Limited Unsponsored ADR (NASDAQ:OPT) have been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $1.3333.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Opthea in a report on Saturday, September 27th.

Opthea Price Performance

Shares of NASDAQ:OPT opened at $3.41 on Friday. Opthea has a 52 week low of $1.79 and a 52 week high of $6.30. The company’s 50 day moving average is $3.41 and its two-hundred day moving average is $3.41.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of OPT. Citadel Advisors LLC acquired a new position in shares of Opthea in the 4th quarter valued at $79,000. Regal Partners Ltd boosted its holdings in shares of Opthea by 78.6% in the 1st quarter. Regal Partners Ltd now owns 5,193,688 shares of the company’s stock valued at $17,710,000 after buying an additional 2,286,285 shares in the last quarter. OLD Mission Capital LLC boosted its holdings in shares of Opthea by 78.7% in the 1st quarter. OLD Mission Capital LLC now owns 19,167 shares of the company’s stock valued at $65,000 after buying an additional 8,439 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Opthea in the 1st quarter valued at $34,000. Finally, Twin Lakes Capital Management LLC boosted its holdings in shares of Opthea by 67.4% in the 1st quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company’s stock valued at $113,000 after buying an additional 13,350 shares in the last quarter. Institutional investors and hedge funds own 55.95% of the company’s stock.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.